Neurological Biomarkers Market
Neurological Biomarkers Market Size, Share & Trends Analysis Report by Biomarker Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers), by Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), and by End Users (Hospital, Clinical Diagnostic Centers, Research Organizations) Forecast Period (2023-2030) Update Available - Forecast 2024-2030
Neurological biomarkers market is anticipated to grow at a significant CAGR of 12.4% during the forecast period. The increase in the prevalence of neurological diseases such as motor neuron disease (MND), Parkinson’s disease (PD), stroke, Alzheimer’s disease (AD), and Huntington’s disease (HD), and the increase in biobanks for addressing unmet requirements in oncology, neuroscience, and cardiovascular disease (CVDs) to accelerate the market growth. According to the Canadian Tissue Repository Network (CTRNet), there are 278 biobanks in the North American region as of February 2021. Furthermore, according to the New South Wales Health Pathology (NSW-HP), there are 74 biobanks, and there are 274 biobanks in the UK as of February 2021, according to the UKCRC-TD, the UK Clinical Research Collaboration Tissue Directory.
In addition, companies including Fujirebio Diagnostics, Inc., Thermo Fisher Scientific Inc., Quanterix, and others are inclined towards adopting various strategies such as partnership, collaboration, and new product launches, that further drive market growth. For instance, in March 2023, Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions. The agreement provides Fujirebio access to clinical samples and data collected as part of the Phase 3 Alzheimer’s disease study.
Segmental Outlook
The global neurological biomarkers market is segmented based on biomarker type, application, and end user. Based on biomarker type, the market is sub-segmented into imaging biomarkers, metabolomics biomarkers, proteomic biomarkers, and genomics biomarkers. Based on the application, the market is sub-segmented into Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Autism Spectrum Disorders, and others. Based on end user, the market is categorized into hospitals, clinical diagnostic centers, research organization. Among the end users, the research organization sub-segment is anticipated to grow at a significant rate in the coming years. An increasing number of researchers are involved in identifying key biomarkers in serum and plasma, and rising government expenditure for R&D centers to drive the segment growth.
The Parkinson’s Disease Sub-Segment is Anticipated to Hold a Considerable Share of the Global Neurological Biomarkers Market
Among the biomarker type, the Parkinson’s disease sub-segment to holds a prominent share of the global neurological biomarkers market. The growth is mainly attributed owing to the rising number of drug approval for the treatment of Parkinson’s disease, coupled with increasing awareness among the people regarding the neurological diseases, drive the segment’s growth. For instance, in January 2023, Neuroderm announced results from its Phase III trial on ND0612, a liquid levodopa/carbidopa. Levodopa temporarily replaces the dopamine brain chemical, and control Parkinson’s motor symptoms (tremor, slowness, stiffness) for longer periods of time and with fewer doses each day. It’s currently available as a pill (to take by mouth), inhaler or gel (for infusion into the small intestine). This treatment is for those people who are suffered form Parkinson’s and are unable to achieve optimal symptom control with oral medications.
Regional Outlooks
The global neurological biomarkers market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. The North American region is anticipated to witness considerable growth in the market. The rise in customer awareness about the use of biomarkers in diagnosing neurological disorders, the availability of technologically advanced products, and improved healthcare infrastructure, are some of the major factors that drive the market growth in the region.
Global Neurological Biomarkers Market Growth, by Region 2023-2030
The North America Region to Hold a Prominent Share of the Global Neurological Biomarkers Market
The North American region is projected to hold a prominent market share in the neurological biomarker market. This high growth is attributed to the rising prevalence of neurological diseases and the increasing number of clinical trials. For instance, according to the Alzheimer Association, nearly 6.7 million Americans age 65 and older are living with Alzheimer's in 2023, and 73% are aged 75 years and above. About 1 in 9 people aged 65 and older has Alzheimer's, and almost two-thirds of Americans with Alzheimer's are women. In addition, rising FDA approval for neurological disorder diseases is another factor that boosts market growth. For instance, in December 2022, the US FDA approved two immunoassays, Elecsys Phospho-Tau (181P) CSF (pTau181) and Elecsys beta-Amyloid (1-42) CSF II (Abeta42), developed by F. Hoffmann-La Roche Ltd. in the US. These two assays measure two important biomarkers-tau proteins and beta-amyloid-in adult patients to confirm the diagnosis of Alzheimer’s disease.
Market Players Outlook
The major companies serving the global neurological biomarkers market include Abbott Laboratories, Bio-Rad Laboratories Inc., Qiagen N.V., Quanterix, Thermo Fisher Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, geographical expansions, partnerships, product launches, and collaborations, to stay competitive in the market. For instance, in September 2020, the National Institutes of Health (NIH) granted research funding of $45.5 million to the University of North Texas Health Science Center for developing additional biomarkers. This funding is used for understanding the pathology of brain aging in Mexican Americans and non-Latino Whites populations.
The Report Covers
- Market value data analysis of 2022 and forecast to 2030.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global neurological biomarkers market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. ByRegion
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight and Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
1.1. Key Company Analysis
3.1. Abbott Laboratories
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Bio-Rad Laboratories Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Qiagen N.V.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Quanterix Corp.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Thermo Fisher Scientific Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
4. Market Segmentation
4.1. Global Neurological Biomarkers Market by Biomarker Type
4.1.1. Imaging Biomarkers
4.1.2. Metabolomics Biomarkers
4.1.3. Proteomic Biomarkers
4.1.4. Genomics Biomarkers
4.2. Global Neurological Biomarkers Market by Application
4.2.1. Alzheimer’s Disease
4.2.2. Parkinson’s Disease
4.2.3. Multiple Sclerosis
4.2.4. Autism Spectrum Disorders
4.2.5. Others (stroke, or epilepsy)
4.3. Global Neurological Biomarkers Market by End User
4.3.1. Hospital
4.3.2. Clinical Diagnostic Centers
4.3.3. Research Organizations
5. Regional Analysis
1.2. North America
1.2.1. US
1.2.2. Canada
1.3. Europe
1.3.1. UK
1.3.2. Germany
1.3.3. Italy
1.3.4. Spain
1.3.5. France
1.3.6. Rest of Europe
1.4. Asia-Pacific
1.4.1. China
1.4.2. India
1.4.3. Japan
1.4.4. South Korea
1.4.5. Rest of Asia-Pacific
1.5. Rest of the World
6. Company Profiles
6.1. Advanced Brain Monitoring, Inc.
6.2. AnaSpec
6.3. Athena Diagnostics, Inc.
6.4. BioMérieux, Inc.
6.5. C?N’s Diagnostics
6.6. Enzo Life Sciences, Inc.,
6.7. Fujirebio Europe N.V
6.8. Imagilys
6.9. Labcorp
6.10. NanoSomiX, Inc
6.11. Neurosteer Ltd.
6.12. Proteome Sciences PLC
6.13. Psynova Neurotech Ltd.
6.14. Roche Diagnostics
1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
2. GLOBAL IMAGING BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBAL METABOLOMICS BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL PROTEOMIC BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
5. GLOBAL GENOMICS BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
7. GLOBAL NEUROLOGICAL BIOMARKERS FOR ALZHEIMER’S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
8. GLOBAL NEUROLOGICAL BIOMARKERS FOR PARKINSON’S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL NEUROLOGICAL BIOMARKERS FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL NEUROLOGICAL BIOMARKERS FOR AUTISM SPECTRUM DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
11. GLOBAL NEUROLOGICAL BIOMARKERS FOR OTHER (STROKE, OR EPILEPSY) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
13. GLOBAL NEUROLOGICAL BIOMARKERS IN HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. GLOBAL NEUROLOGICAL BIOMARKERS IN CLINICAL DIAGNOSTICS CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
15. GLOBAL NEUROLOGICAL BIOMARKERS IN RESEARCH ORGANIZATION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
17. NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
18. NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
19. NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
20. NORTH AMERICAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
21. EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
22. EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
23. EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
24. EUROPEAN NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
25. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
26. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
27. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
28. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
29. REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
30. REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2022-2030 ($ MILLION)
31. REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
32. REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY BIOLOGICAL TYPE, 2022 VS 2030 (%)
2. GLOBAL IMAGING BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
3. GLOBAL METABOLOMICS BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
4. GLOBAL PROTEOMIC BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
5. GLOBAL GENOMICS BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
7. GLOBAL NEUROLOGICAL BIOMARKERS FOR ALZHEIMER’S DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
8. GLOBAL NEUROLOGICAL BIOMARKERS FOR PARKINSON’S DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
9. GLOBAL NEUROLOGICAL BIOMARKERS FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
10. GLOBAL NEUROLOGICAL BIOMARKERS FOR AUTISM SPECTRUM DISORDERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
11. GLOBAL NEUROLOGICAL BIOMARKERS FOR OTHERS (STROKE OR EPILEPSY) MARKET SHARE BY REGION, 2022 VS 2030 (%)
12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY END USER, 2022 VS 2030 (%)
13. GLOBAL NEUROLOGICAL BIOMARKERS IN HOSPITAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
14. GLOBAL NEUROLOGICAL BIOMARKERS IN CLINICAL DIAGNOSTICS CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
15. GLOBAL NEUROLOGICAL BIOMARKERS IN RESEARCH ORGANIZATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
17. US NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
18. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
19. UK NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
20. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
21. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
22. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
23. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
24. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
25. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
26. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
27. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
28. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
29. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
30. REST OF THE WORLD NEUROLOGICAL BIOMARKERS MARKET SIZE, 2022-2030 ($ MILLION)
